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Abstract
Background: Redistribution of nuclear TAR DNA binding protein 43 (TDP-43) to the cytoplasm
and ubiquitinated inclusions of spinal motor neurons and glial cells is characteristic of amyotrophic
lateral sclerosis (ALS) pathology. Recent evidence suggests that TDP-43 pathology is common to
sporadic ALS and familial ALS without SOD1 mutation, but not SOD1-related fALS cases.
Furthermore, it remains unclear whether TDP-43 abnormalities occur in non-ALS forms of motor
neuron disease. Here, we characterise TDP-43 localisation, expression levels and post-translational
modifications in mouse models of ALS and spinal muscular atrophy (SMA).
Results: TDP-43 mislocalisation to ubiquitinated inclusions or cytoplasm was notably lacking in
anterior horn cells from transgenic mutant SOD1G93A mice. In addition, abnormally phosphorylated
or truncated TDP-43 species were not detected in fractionated ALS mouse spinal cord or brain.
Despite partial colocalisation of TDP-43 with SMN, depletion of SMN- and coilin-positive Cajal
bodies in motor neurons of affected SMA mice did not alter nuclear TDP-43 distribution,
expression or biochemistry in spinal cords.
Conclusion: These results emphasise that TDP-43 pathology characteristic of human sporadic
ALS is not a core component of the neurodegenerative mechanisms caused by SOD1 mutation or
SMN deficiency in mouse models of ALS and SMA, respectively.
Background
Spinal muscular atrophy (SMA) and amyotrophic lateral
sclerosis (ALS) are the commonest forms of human motor
neuron disease in children and adults, respectively. The
disorders share the feature of vulnerability of lower motor
neurons in the anterior horn of the spinal cord, implicat-
ing possible common factors in motor neuron degenera-
tion. ALS also affects upper motor neurons in the cerebral
cortex, and a proportion of cases demonstrate more wide-
spread changes that overlap pathologically and clinically
with frontotemporal lobar degeneration (FTLD). While
SMA is an autosomal recessive genetic disorder caused by
deletions of the survival motor neuron 1 (SMN1) gene
with resulting SMN deficiency [1], only about 5–10% of
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ALS cases are familial (fALS) [2,3]. Dominant mutations
in the superoxide dismutase 1 gene (SOD1) cause approx-
imately 20% of the familial cases, and thus contribute the
largest single group of hereditary ALS. The genetic contri-
bution of single genes or at risk haplotypes to the majority
of sporadic cases is currently thought to be modest [4].
Novel insights into the aetiopathogenesis of ALS have
come from the discovery of the TAR DNA binding protein
(TDP-43) as a major constituent of the characteristic ubiq-
uitinated inclusions found in neuronal and glial cells in
ALS [5]. While ubiquitination of proteins is no proof of
their pathogenicity, the role of TDP-43 as a disease causa-
tive protein is suggested by the observation that, in
affected cells, TDP-43 is absent from its normal location
in the nucleus and redistributed to the cytoplasm, where
it displays various staining patterns from diffuse distribu-
tion to strict co-localisation in ubiquitinated aggregates
[6,7]. In addition to the abnormal TDP-43 distribution,
biochemical analysis of disease tissue reveals a character-
istic disease signature of TDP-43 in urea soluble protein
extracts, characterised on Western blots by high molecular
weight species, 25 kD C-terminal fragments and 45 kD
hyperphosphorylated protein bands [5]. Further confir-
mation of the pathogenic role of TDP-43 comes from a
series of publications reporting mutations in TARDBP in
both familial and sporadic ALS. An increasing number of
mutations have been described which predominantly
affect the conserved C-terminal glycine-rich domain of
TDP-43 predicting abnormal RNA or protein interactions.
Furthermore, the existence of TARDBP mutations in auto-
somal dominant ALS with demonstrable TDP-43 pathol-
ogy strengthens the evidence for a causal role of TDP-43
in inherited forms of motor neuron disease. [8-12].
At present, it is unclear whether the pathogenic effect of
TDP-43 results from the formation of toxic aggregates, or
from the loss of its nuclear function. It is noteworthy that
in mammals TDP-43 has been shown to interact in the
nucleus with the SMN protein, deficiency of which results
in the motor neuron disease SMA [13]. SMN is present in
the cytoplasm and nucleus of mammalian cells. In the lat-
ter, it forms discrete nonmembrane bound structures
called 'gems' (for gemini of coiled bodies). Gems are in a
complex relationship with Cajal bodies, structures charac-
terised by the presence of coilin, and gems and Cajal bod-
ies colocalise to varying degrees depending on the stage of
development and tissue type. Motor neurons show the
highest degree of colocalisation between gems and Cajal
bodies [14]. If SMN levels are reduced in cells [15] or
mice[16], Cajal body formation as assessed by staining
with anti-coilin antibody is impaired. Given the interac-
tion between TDP-43 and SMN in the nucleus, one
hypothesis is that loss of TDP-43 from the nucleus could
lead to motor neuron degeneration in ALS, in part because
of an alteration in nuclear SMN function. Conversely,
nothing is known about a potential role of TDP-43 in
SMA.
While the pathological features of ALS described above
have been replicated in cases of sporadic ALS, they are
probably absent in cases of fALS caused by SOD1 muta-
tions [17]. Sporadic and non-SOD1-related fALS, together
with certain types of FTLD, can therefore be seen as TDP-
43 spectrum proteinopathies, whereas SOD1 fALS may be
a phenocopy of sporadic ALS with a different aetiopatho-
genesis [18]. This also means that the most commonly
used mouse models of ALS, in which mutant SOD1 is
overexpressed [19], might not accurately reflect the
pathology found in the vast majority of human cases.
Indeed, there is evidence that there is no TDP-43 redistri-
bution in three mouse models of SOD1 ALS [20]. How-
ever, mouse models do not always reflect every aspect of
human disease [21], and the absence of TDP-43 redistri-
bution does not rule out the presence of abnormal bio-
chemical TDP-43 species. In particular, while ALS in
humans is clearly an age dependent disease, all aspects of
ALS neuropathology might not emerge within the short
lifespan of the mouse.
In the present study, we confirmed the previously
described finding of absent TDP-43 redistribution to the
neuronal cytoplasm in the SOD1G93A model of ALS. We
have extended these findings to address the question of
whether TDP-43 is altered in its nuclear distribution,
expression level or biochemical state. To examine a poten-
tial role of TDP-43 in SMA, we then looked for evidence
of TDP-43 redistribution, altered expression or biochem-
istry in a commonly used model of moderate to severe
SMA, the 'SMNΔ7 mouse' [22].
Methods
Transgenic mice
Transgenic SOD1G93A mice derived from the B6SJL-TgN
(SOD1-G93A) 1Gur line (Jackson Laboratory) were back-
crossed onto a pure C57BL6 background and generously
provided by Prof. Pamela Shaw (University of Sheffield).
Mice were maintained by mating heterozygous transgenic
males with C57BL6 females. Disease endpoint mice (post-
natal day 120) and age-matched wild-type mice were
killed by lethal injection (Pentoject, IP) in accordance
with Home Office regulations. Transgenic Smn+/-
;SMN2;SMNΔ7 mice ([22]) were maintained as heterozy-
gote breeding pairs. Homoyzgote Smn-/-;SMN2;SMNΔ7
mice reached the disease endpoint at postnatal day 13
(P13) and were killed with wild-type littermates as
described above. A minimum of 3 mice of each genotype
were used for each procedure below. All genotypes were
confirmed by routine PCR analysis using tail genomic
DNA.BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
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Immunohistochemistry and Immunofluorescence
Mice were transcardially perfused with phosphate buff-
ered saline (PBS) followed by 4% paraformaldehyde
(PFA) in 0.1 M phosphate buffer under terminal anaesthe-
sia with pentobarbitone. Lumbar spinal cords were dis-
sected, post-fixed in 4% PFA overnight at 4°C and
embedded in paraffin. 6 μm horizontal sections were
dewaxed and autoclaved for 10 minutes at 121°C in 0.01
M citrate buffer pH 6.0 for antigen retrieval. Immunos-
taining was performed using overnight incubation at 4°C
with mouse anti-SMN (BD Transduction lab, 1:320), rab-
bit anti-TDP-43 (Proteintech 1:500), rabbit anti-p80 coi-
lin (Dundee Cell products 1:200) and rabbit anti-
ubiquitin (Dako 1:500). Primary antibodies were visual-
ised using a Dako REAL EnVision detection system (Dako
UK Ltd). For immunofluorescence, sections were blocked
in 4% normal goat serum, 2% BSA in PBS-T for 30 min-
utes prior to primary antibody incubation. Alexa Fluor
488 and 568 conjugated antibodies raised in goat were
used as secondaries (1:500, Molecular Probes, Invitro-
gen). Nuclei were counterstained with DAPI.
Image analysis
2 spinal cord sections were analysed for each of 3 animals
of each genotype. Per section, five large alpha motor neu-
rons were examined per ventral horn (20 per animal).
Motor neurons were identified by their location in the
ventral horn, large nucleus, prominent nucleolus, polygo-
nal shape and relatively large size. Only cells with clearly
visible nucleolus were chosen for analysis. Images were
captured using a Zeiss LSM 510 laser scanning microscope
with a 63× oil immersion objective and 2× digital zoom.
Image analysis was performed using Image J software
(NIH). In order to quantify nuclear TDP-43, images of
motor neuron nuclei were displayed in Image J with auto-
matic setting of brightness and contrast. All distinct speck-
les of nuclear TDP-43 fluorescence with a minimum
diameter of 1 μm were then counted manually using the
point picker function. Cajal bodies and TDP-43 speckles
were counted blind to genotype.
Sequential biochemical fractionation and immunoblotting
Brains and lumbar spinal cords were dissected, snap fro-
zen and sequentially extracted as previously described [5].
Briefly, tissues were extracted at 200 mg/ml in low salt
(LS) buffer by sonicating for 15 sec, incubating on ice for
30 min and centrifuging at 14,000 rpm for 30 min at 4°C.
Pellets were sequentially extracted in high salt Triton (TX),
sarkosyl (SARK) and urea (UR) buffers as above. Proteins
were quantified using the reducing agent-compatible BCA
assay kit (Pierce, Rockford, IL). Samples (50 μg) were elec-
trophoresed through 12.5% SDS-polyacrylamide gels and
transferred to nitrocellulose membranes. Blots were
blocked with 5% (w/v) non-fat milk in TBST for 1 hr and
incubated with rabbit TDP-43 (1:1,500), SOD1 (1:1,000,
Calbiochem) or mouse β-actin (1:5000, Abcam) antibod-
ies overnight at 4°C. Blots were probed with HRP-conju-
gated antibodies (1:10,000, Amersham) and developed
with enhanced chemiluminescence reagents (Roche).
For protein dephosphorylation, urea extracts were dia-
lysed against 50 mM Tris-HCl, pH 7.9, 100 mM NaCl, 10
mM MgCl2 and 1 mM DTT using Slide-A-Lyzer mini dial-
ysis units (Pierce). Dialysates (50 μg) were treated with 10
U calf intestinal phosphatase (New England Biolabs) for
1 hr at 37°C and the reaction was terminated by addition
of SDS loading buffer.
Real-time PCR
Frontal cortex, brainstem, cerebellum and lumbar spinal
cord were dissected and snap-frozen. RNA was extracted
using the RNeasy kit (Qiagen) and cDNA was reversed
transcribed using oligo(dT) primers and Superscript II
(Invitrogen). qRT-PCR was performed using 900 nM for-
ward 5'-TCCCCTGGAAAACAACAGAG-3' and reverse 5'-
CCAGACGAGCCTTTGAGAAG-3' mouse TARDBP prim-
ers with Power SYBR Green master mix on an ABI Prism
7700 real-time PCR machine (Applied Biosystems). TAR-
DBP levels were normalised against amplified GAPDH
levels using forward 5'-TGTGACTTCAACAGCAACTC-3'
and reverse 5'-GTGGACCTCATGGCCTACAT-3' primers.
Fold change from wild-type mice was calculated for each
tissue. Genotypes were measured in triplicate and com-
pared with an unpaired t-test using GraphPad Prism 3.0
software (GraphPad).
Results
Ubiquitinated cytoplasmic inclusions but no TDP-43 
redistribution in SOD1G93A anterior horn cells
We first examined spinal cords of two common mouse
models of motor neuron disease for ubiquitin or TDP-43
histopathology, completely screening all stained sections
visually for abnormal neuronal TDP-43 localisation (fig-
ure 1). Motor neurons in terminal SOD1G93A mice, but
not WT animals, showed extensive cytoplasmic staining
with ubiquitin antibodies (figure 1b,c). However, TDP-43
immunoreactivity was confined to nuclei only in both
genotypes (figure 1e,f). Thus, in contrast to sporadic and
most familial cases of human ALS, TDP-43 did not aggre-
gate into distinct inclusions and was not mislocalised
from the nucleus to the cytoplasm in anterior horn cells of
SOD1G93A mice. Interestingly, it appeared that some of the
nuclei of presumed reactive astroglia in endstage
SOD1G93A mice showed a weaker TDP-43 signal than glia
in WT litter mates (figures 1e,f). Neither cytoplasmic TDP-
43 redistribution, nor cytoplasmic ubiquitin staining was
present in spinal cords of endstage SMA animals (figure
1h,i).BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
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Spinal cord sections of transgenic SOD1G93A mice (a-c, f) show anterior horn cell degeneration, hyaline aggregates (arrow) and  vacuolation (a) not present in corresponding wild-type (d) Figure 1
Spinal cord sections of transgenic SOD1G93A mice (a-c, f) show anterior horn cell degeneration, hyaline aggre-
gates (arrow) and vacuolation (a) not present in corresponding wild-type (d). Amorphous cytoplasmic aggregates 
are ubiquitinated and occasionally extend into proximal processes (b, c). TDP-43 remains located in the nucleus of anterior 
horn cells and shows no distinct aggregates (f). The appearances are essentially indistinguishable from wild-type (e) apart from 
possible slightly weaker TDP-43 signal in presumed reactive glia (f). Samples from transgenic Smn-/-;SMN2;SMNΔ7 spinal cord 
(g-i) show residual motor neurons (g) without ubiquitin positivity (h) and preserved nuclear TDP-43 signal (i). Scale bar in all 
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Reduction of Cajal bodies in SMA animals, but no 
alteration of nuclear TDP-43 architecture in SMA or 
SOD1G93A animals
Despite the lack of cytoplasmic TDP-43 pathology, its
nuclear distribution may nonetheless be altered in motor
neuron disease. In healthy motor neurons of WT mice,
SMN localised to the cytoplasm and nuclear Cajal bodies
(figure 2). In SMA animals, there was a marked reduction
of cytoplasmic SMN staining as well as significant disrup-
tion of Cajal bodies (figures 2b, 3). To confirm that Cajal
body depletion was not an artefact of the overall reduc-
tion in SMN immunoreactivity, we used coilin as an alter-
native marker of Cajal bodies. Coilin co-localised with
SMN in motor neurons of WT animals (figure 4a), and
was accordingly reduced in SMA animals (figure 4b).
There was no difference in SMN staining pattern or
number of Cajal bodies between the SOD1G93A and WT
animals (figures 2, 3, 4). Of note, the Cajal body count
was significantly higher in the Smn+/+;SMN2;SMNΔ7
animals than in the SOD1G93A and WT animals. This dif-
ference might be due to the presence of increased levels of
SMNΔ7 expressed from the SMNΔ7 and SMN2 transgenes
in the SMA animals, but the different developmental state
(13 days vs 4 months) or the different background strain
could also play a role.
We found that the distribution of TDP-43 within the
nucleus was unaltered both in SOD1G93A and SMA ani-
mals when compared to their WT controls (figure 2). TDP-
43 staining was granular, with sparing of the nucleolus,
but showed discrete areas of high signal intensity suggest-
ing the presence of distinct nuclear speckles. Although dis-
tinct accumulation of TDP-43 in discrete speckles is a
consistent observation, it is unclear whether this has any
functional significance. Furthermore, there was partial co-
localisation with Cajal bodies in about 30% of cells exam-
ined (figure 2a).
To quantify the number of TDP-43 speckles per section,
we used an auto-thresholding algorithm to separate areas
of high signal from background granular staining. Com-
parison of TDP-43 nuclear speckles between WT and
motor neuron disease animals revealed no significant dif-
ference (figure 5). Several limitations apply to this
approach, however. First, we limited our analysis to motor
neurons that were easily identifiable on the basis of their
shape, possibly missing diseased cells with altered mor-
phology. Likewise, we did not distinguish between cells
(a) Wild-type mouse spinal cord sections stained for TDP-43 and SMN Figure 2
(a) Wild-type mouse spinal cord sections stained for TDP-43 and SMN. Large alpha motor neurons show diffuse 
cytoplasmic SMN stain and punctate nuclear SMN, Cajal bodies. TDP-43 shows only nuclear and no cytoplasmic staining. (b) 
Representative merged TDP-43 and SMN stains for all genotypes. Note absence of Cajal bodies in the SMA mouse. The pat-
tern of TDP-43 immunoreactivity is unaltered in SOD1G93A and SMA mice. Scale bar = 20 μm.BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
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that harboured ubiquitinated inclusions and those that
did not. Thirdly, while quantification of TDP speckles is
useful as an addition to qualitative assessment, the defini-
tion of what constitutes a TDP speckle is arbitrary and
dependent on the intensity of the stain and the threshold
setting during image acquisition.
No change in TDP-43 expression or post-translational 
modification in SOD1G93A or SMA animals
In spite of evidence against TDP-43 redistribution or alter-
ation of nuclear architecture, we additionally assessed
whether abnormal TDP-43 biochemical species were
present in SOD1G93A or SMA animals. Brain and spinal
cords were sequentially extracted in buffers of increasing
ionic and detergent strength then analysed with immuno-
blotting. Full-length TDP-43 and a lower migrating spe-
cies were detected in most fractions of transgenic mice,
particularly abundant in LS extracts (figures 6a, 7a). How-
ever, the appearance and migration of TDP-43 was not
altered compared to WT tissues. Endogenous and trans-
genic SOD1 was distributed across all fractions in ALS tis-
sue with increased solubility of dimeric mutant SOD1 in
urea (figure 6a). Likewise, endogenous SMN was found in
all fractions in control brain, while doublet bands of puta-
tive SMN transgenic products mainly localised to LS
extracts in SMA (figure 7a). To test for the presence of
hyperphosphorylated TDP-43 in mice, urea extracts from
CNS were dialysed and phosphatase treated (figure 6b).
The persistence of an upper band suggests no phospho-
TDP-43 species from this experiment.
Despite the lack of pathologic TDP-43 protein in
SOD1G93A or SMA mice, its transcription or mRNA stabil-
ity may be regionally dysregulated in disease. Messenger
RNA levels of TDP-43 were therefore quantified from
three brain sub-regions and spinal cord using real-time
PCR (figures 6c, 7b). TDP-43 transcript levels were similar
across frontal cortex, brainstem, cerebellum and spinal
cord in disease versus control mice.
Discussion & conclusion
To our knowledge, this is the first study to examine the
expression of TDP-43 at morphological and biochemical
levels in mouse models of both ALS and SMA. It was
prompted by two main questions: firstly, we wanted to
confirm the previously reported lack of significant TDP-43
Quantification of Cajal bodies per motor neuron nucleus for each genotype Figure 3
Quantification of Cajal bodies per motor neuron nucleus for each genotype. Unpaired two-tailed t-test, p = 0.0004 
(***) and p = 0.002 (**). Error bars represent standard deviation.BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
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pathology in SOD1-mediated familial ALS in humans
[17,23] and mouse models [20]. Independent confirma-
tion of this observation is important, because the
SOD1G93A  mouse model is the most commonly used
model for human ALS and has informed many transla-
tional clinical trials. Understandably, the possibility that
SOD-1-associated ALS may be pathogenetically distinct
from sporadic ALS and most other forms of familial ALS,
has caused controversy [24].
We found no evidence of TDP-43 mislocalisation or alter-
ation of expression at the level of protein or mRNA in tis-
sue extracts from endstage SOD1G93A mice. In addition,
the absence of C-terminally cleaved TDP-43 species in
urea fractions of tissues, as well as lack of TDP-43 hyper-
phosphorylation, is clear evidence that the SOD1G93A
mouse model does not share the characteristic pathologi-
cal and biochemical hallmarks of TDP-43 pathology
known from human sporadic ALS cases. This has impor-
tant implications for the use of these mice in drug trials for
ALS. While some drugs that showed efficacy in mouse
drug trials, e.g. riluzole [25] have marginal efficiency in
humans, this probably means that they exert a non-spe-
cific effect or act downstream from the disease-initiating
pathological events. Clearly, a TDP-43 mouse model of
ALS is needed to assess the degree of overlap between
pathways of motor neuron degeneration in SOD1 and
TDP-43 mediated disease for more efficient drug develop-
ment. Although the core features of human sporadic TDP-
43 pathology were not identified in our experimental set-
ting of SOD1G93A-mediated disease, and at least one other
study has reported similar findings in G37R and G85R
SOD1 transgenic mouse models [20], it is conceivable
that SOD1 and TDP-43 pathways interact at other, more
subtle or as yet unidentified levels. For example, tempo-
rary alterations in TDP-43 expression or function over the
course of SOD1-related ALS, cell-type specific changes
(glial versus neuronal), or variations relating to specific
SOD1 genotypes remain to be identified. Recent work
identifying a covalently altered SOD1 species which is
common to sALS and SOD1-fALS spinal cord suggests that
it would be premature to conclude that there is no overlap
between TDP-43 and SOD1 pathology [26].
The second aim of this study was to address the possibility
that TDP-43 expression or nuclear architecture might be
altered in SMA, which is characterised by low levels of
SMN, a protein known to interact with TDP-43 in the
nucleus [13]. While there is a distinct possibility that SMA
is caused by loss of a neuron-specific, non-canonical func-
tion of SMN, e.g. in neuronal development, neurite out-
growth or axonal transport [27], there is mounting
evidence that SMN deficiency leads to tissue-dependent
differential defects in snRNP biogenesis and splicing
[28,29]. This is in keeping with our finding of a marked
reduction of Cajal bodies, which are sites of ribonuclear
protein (RNP) maturation and snRNA modification
[30,31], in motor neuron nuclei of SMA animals, and a
(a) Wild-type mouse spinal cord sections stained for coilin and SMN Figure 4
(a) Wild-type mouse spinal cord sections stained for coilin and SMN. Coilin co-localises with SMN in the motor neu-
ron nucleus. (b) Coilin immunohistochemistry confirms reduction of Cajal bodies in the SMA mouse, but equal distribution 
between SOD1G93A and WT animals. Scale bar = 20 μm.BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
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Quantification of neuronal TDP-43 nuclear speckles in spinal cord sections Figure 5
Quantification of neuronal TDP-43 nuclear speckles in spinal cord sections. Approximately 0.9 μm thick confocal 
section through representative motor neuron nucleus (a) and automatic setting of brightness and contrast in Image J (b). No 
significant difference in TDP-43 speckle number is obvious between genotypes (c).BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
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potential site of SMN/TDP-43 interaction. The reduction
in SMN protein and Cajal bodies was not accompanied by
an alteration of TDP-43 mRNA or protein levels, nor a
qualitative or quantitative change in nuclear distribution
of TDP-43. This implies that SMA pathogenesis is not
mediated by TDP-43, although, given the asymmetrical
distribution of the two proteins, the abundance of TDP-43
in the nucleus might have masked small regional changes.
A more rigorous examination of TDP-43 expression levels
in laser-capture dissected anterior horn cells rather than
whole tissue extracts may be needed to arrive at a defini-
tive answer. In addition, there was no evidence that TDP-
43 is up-regulated in compensation for SMN deficiency in
the SMNΔ7 model of SMA.
While we were able to examine the effect of SMN defi-
ciency on TDP-43 in vivo in the present study, we were
unable to address the equally interesting question of what
effect loss of nuclear TDP-43 might have on levels and dis-
tribution of SMN. In a study of frontotemporal lobar
degeneration, Neumann and co-workers could not detect
SMN in ubiquitinated, TDP-43 positive inclusions, and
the SMN staining pattern using standard brightfield
microscopy, as well as protein levels on a Western blot,
were unaltered between disease and control cases [32].
However, it remains possible that loss of TDP-43 will lead
to derangement of Cajal bodies, with resulting deficits in
snRNP maturation. The fact that we did not observe any
changes in SMN distribution in the SOD1G93A model of
TDP-43 protein and transcript levels in CNS of transgenic SOD1 G93A mice compared with age matched controls (a) Immu- noblot analysis of brain and spinal cord extracts from wild-type (WT) and transgenic mice (SOD1G93A) at 4 months of age Figure 6
TDP-43 protein and transcript levels in CNS of transgenic SOD1 G93A mice compared with age matched con-
trols (a) Immunoblot analysis of brain and spinal cord extracts from wild-type (WT) and transgenic mice 
(SOD1G93A) at 4 months of age. Open arrow, putative dimeric hSOD1 species. (b) Phosphatase treatment of representa-
tive brain urea extracts. (c) Quantitative RT-PCR analysis of brain regions and spinal cords from mice.BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
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ALS does not refute this hypothesis, as the TDP-43 distri-
bution was, unlike in human sporadic ALS, unaltered.
Further studies looking at SMN in TDP-43 positive ALS,
using autopsy material or a model organism, are needed
to assess this question.
Authors' contributions
BT performed immunoblotting and real time PCR and
drafted the manuscript. DB performed immunohisto-
chemistry, confocal microscopy and drafted the manu-
script. NP was responsible for animal breeding and
preparation and carried out immunoblotting. JS per-
formed immunhistochemistry and immunoblotting. KT
and OA jointly conceived of the study, participated in its
design and coordination and edited the final manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported by funding from the SMA Trust, the Muscular 
Dystrophy Campaign and an Australian CJ Martin Fellowship (BJT).
References
1. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L,
Benichou B, Cruaud C, Millasseau P, Zeviani M, et al.: Identification
and characterization of a spinal muscular atrophy-determin-
ing gene.  Cell 1995, 80(1):155-165.
2. Logroscino G, Beghi E, Zoccolella S, Palagano R, Fraddosio A, Simone
IL, Lamberti P, Lepore V, Serlenga L: Incidence of amyotrophic
lateral sclerosis in southern Italy: a population based study.
J Neurol Neurosurg Psychiatry 2005, 76(8):1094-1098.
3. O'Toole O, Traynor BJ, Brennan P, Sheehan C, Frost E, Corr B,
Hardiman O: Epidemiology and clinical features of amyo-
trophic lateral sclerosis in Ireland between 1995 and 2004.  J
Neurol Neurosurg Psychiatry 2008, 79(1):30-32.
4. Schymick JC, Talbot K, Traynor BJ: Genetics of sporadic amyo-
trophic lateral sclerosis.  Hum Mol Genet 2007, 16(Spec No
2):R233-242.
5. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC,
Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al.: Ubiqui-
TDP-43 protein and transcript levels in CNS of SMA mice (Smn-/-;SMN2;SMNΔ7) and age-matched littermates (a) Immunoblot  analysis of brain and spinal cord extracts from wild-type (WT) and affected (SMA) mice at 13 days of age Figure 7
TDP-43 protein and transcript levels in CNS of SMA mice (Smn-/-;SMN2;SMNΔ7) and age-matched littermates 
(a) Immunoblot analysis of brain and spinal cord extracts from wild-type (WT) and affected (SMA) mice at 13 
days of age. (b) Quantitative RT-PCR analysis of brain regions and spinal cords from mice.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Neuroscience 2008, 9:104 http://www.biomedcentral.com/1471-2202/9/104
Page 11 of 11
(page number not for citation purposes)
tinated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis.  Science 2006, 314(5796):130-133.
6. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ,
Foong C, White CL 3rd, Schneider JA, Kretzschmar HA, et al.: TDP-
43 in familial and sporadic frontotemporal lobar degenera-
tion with ubiquitin inclusions.  Am J Pathol 2007, 171(1):227-240.
7. Fujita Y, Mizuno Y, Takatama M, Okamoto K: Anterior horn cells
with abnormal TDP-43 immunoreactivities show fragmenta-
tion of the Golgi apparatus in ALS.  J Neurol Sci 2008.
8. Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D,
Hatanpaa KJ, White CL 3rd, Bigio EH, Caselli R, et al.:  TDP-43
A315T mutation in familial motor neuron disease.  Ann Neurol
2008.
9. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley
S, Durnall JC, Williams KL, Buratti E, et al.: TDP-43 Mutations in
Familial and Sporadic Amyotrophic Lateral Sclerosis.  Science
2008.
10. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Velde
CV, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, et al.: TAR-
DBP mutations in individuals with sporadic and familial
amyotrophic lateral sclerosis.  Nat Genet 2008.
11. Van Deerlin VM, Leverenz JB, Bekris LM, Bird TD, Yuan W, Elman LB,
Clay D, Wood EM, Chen-Plotkin AS, Martinez-Lage M, et al.: TAR-
DBP mutations in amyotrophic lateral sclerosis with TDP-43
neuropathology: a genetic and histopathological analysis.
Lancet Neurol 2008.
12. Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, Koyama A, Eguchi
H, Tsujino A, Ikeuchi T, Kakita A, et al.: TDP-43 mutation in famil-
ial amyotrophic lateral sclerosis.  Ann Neurol 2008,
63(4):538-542.
13. Wang IF, Reddy NM, Shen CK: Higher order arrangement of the
eukaryotic nuclear bodies.  Proc Natl Acad Sci USA 2002,
99(21):13583-13588.
14. Young PJ, Le TT, Dunckley M, Nguyen TM, Burghes AH, Morris GE:
Nuclear gems and Cajal (coiled) bodies in fetal tissues: nucle-
olar distribution of the spinal muscular atrophy protein,
SMN.  Exp Cell Res 2001, 265:252-261.
15. Girard C, Neel H, Bertrand E, Bordonne R: Depletion of SMN by
RNA interference in HeLa cells induces defects in Cajal body
formation.  Nucleic Acids Res 2006, 34:2925-2932.
16. Frugier T, Tiziano FD, Cifuentes-Diaz C, et al.: Nuclear targeting
defect of SMN lacking the C-terminus in a mouse model of
spinal muscular atrophy.  Hum Mol Genet 2000, 9:849-858.
17. Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ,
Kwong LK, Forman MS, Ravits J, Stewart H, et al.: Pathological
TDP-43 distinguishes sporadic amyotrophic lateral sclerosis
from amyotrophic lateral sclerosis with SOD1 mutations.
Ann Neurol 2007, 61(5):427-434.
18. Kwong LK, Uryu K, Trojanowski JQ, Lee VM: TDP-43 proteinopa-
thies: neurodegenerative protein misfolding diseases with-
out amyloidosis.  Neurosignals 2008, 16(1):41-51.
19. Turner BJ, Talbot K: Transgenics, toxicity and therapeutics in
rodent models of mutant SOD1-mediated familial ALS.  Prog
Neurobiol 2008, 85(1):94-134.
20. Robertson J, Sanelli T, Xiao S, Yang W, Horne P, Hammond R, Pioro
EP, Strong MJ: Lack of TDP-43 abnormalities in mutant SOD1
transgenic mice shows disparity with ALS.  Neurosci Lett 2007,
420(2):128-132.
21. Hafezparast M, Ahmad-Annuar A, Wood NW, Tabrizi SJ, Fisher EM:
Mouse models for neurological disease.  Lancet Neurol 2002,
1(4):215-224.
22. Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, Coovert DD,
Gavrilina TO, Xing L, Bassell GJ, Burghes AH: SMNDelta7, the
major product of the centromeric survival motor neuron
(SMN2) gene, extends survival in mice with spinal muscular
atrophy and associates with full-length SMN.  Hum Mol Genet
2005, 14(6):845-857.
23. Tan CF, Eguchi H, Tagawa A, Onodera O, Iwasaki T, Tsujino A,
Nishizawa M, Kakita A, Takahashi H: TDP-43 immunoreactivity
in neuronal inclusions in familial amyotrophic lateral sclero-
sis with or without SOD1 gene mutation.  Acta Neuropathol
2007, 113(5):535-542.
24. Rothstein JD: TDP-43 in amyotrophic lateral sclerosis: patho-
physiology or patho-babel?  Ann Neurol 2007, 61(5):382-384.
25. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall
ED: Benefit of vitamin E, riluzole, and gabapentin in a trans-
genic model of familial amyotrophic lateral sclerosis.  Ann
Neurol 1996, 39(2):147-157.
26. Gruzman A, Wood WL, Alpert E, Prasad MD, Miller RG, Rothstein
JD, Bowser R, Hamilton R, Wood TD, Cleveland DW, et al.: Com-
mon molecular signature in SOD1 for both sporadic and
familial amyotrophic lateral sclerosis.  Proc Natl Acad Sci USA
2007, 104(30):12524-12529.
27. Briese M, Esmaeili B, Sattelle DB: Is spinal muscular atrophy the
result of defects in motor neuron processes?  Bioessays 2005,
27(9):946-957.
28. Gabanella F, Butchbach ME, Saieva L, Carissimi C, Burghes AH, Pelliz-
zoni L: Ribonucleoprotein assembly defects correlate with
spinal muscular atrophy severity and preferentially affect a
subset of spliceosomal snRNPs.  PLoS ONE 2007, 2(9):e921.
29. Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim M, Dreyfuss G:
SMN deficiency causes tissue-specific perturbations in the
repertoire of snRNAs and widespread defects in splicing.  Cell
2008, 133(4):585-600.
30. Ogg SC, Lamond AI: Cajal bodies and coilin – moving towards
function.  J Cell Biol 2002, 159(1):17-21.
31. Stanek D, Neugebauer KM: The Cajal body: a meeting place for
spliceosomal snRNPs in the nuclear maze.  Chromosoma 2006,
115(5):343-354.
32. Neumann M, Igaz LM, Kwong LK, Nakashima-Yasuda H, Kolb SJ,
Dreyfuss G, Kretzschmar HA, Trojanowski JQ, Lee VM: Absence of
heterogeneous nuclear ribonucleoproteins and survival
motor neuron protein in TDP-43 positive inclusions in fron-
totemporal lobar degeneration.  Acta Neuropathol 2007,
113(5):543-548.